GVK Bio, Crelux Partner on Drug Discovery Platform | GenomeWeb

NEW YORK (GenomeWeb News) - GVK Biosciences is collaborating with Crelux to offer biopharmaceutical companies an integrated drug discovery and development platform for use in structure-based drug design programs, Hyderabad, India-based GVK Bio said today.

GVK Bio will conduct in silico, in vitro, and in vivo studies and functions related to preclinical candidate nomination, while Munich-based Crelux will perform multifaceted structural studies toward X-ray elucidation of fragment or lead target complexes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.